Ablexis
Ablexis is a biopharmaceutical company specializing in licensing its innovative AlivaMab Mouse platform for antibody drug discovery. The company focuses on providing efficient, diverse, and high-quality therapeutic antibody candidates through its patented transgenic mouse technology. With a strong emphasis on scientific innovation and strategic partnerships, Ablexis aims to accelerate the development of next-generation human therapeutic antibodies, reduce risks in drug discovery, and expand access to its platform for global pharmaceutical and biotech companies.
Industries
Nr. of Employees
small (1-50)
Ablexis
10350 Barnes Canyon Road, Suite 100, San Diego, CA 92121
Patents
Genetic engineering of non-human animals for the production of chimeric antibodies
US-11352444-B2
View DetailsGenetic engineering of non-human animals for the production of chimeric antibodies
US-11242409-B2
View DetailsGenetic engineering of non-human animals for the production of chimeric antibodies
US-11220555-B2
View DetailsGenetic engineering of non-human animals for the production of chimeric antibodies
US-11104743-B2
View DetailsGenetic engineering of non-human animals for the production of chimeric antibodies
US-11104744-B2
View Details
Genetic engineering of non-human animals for the production of chimeric antibodies
US-11352444-B2
View DetailsGenetic engineering of non-human animals for the production of chimeric antibodies
US-11242409-B2
View DetailsGenetic engineering of non-human animals for the production of chimeric antibodies
US-11220555-B2
View DetailsGenetic engineering of non-human animals for the production of chimeric antibodies
US-11104743-B2
View DetailsGenetic engineering of non-human animals for the production of chimeric antibodies
US-11104744-B2
View DetailsProducts
Transgenic mouse platform for human therapeutic antibody discovery
A validated transgenic animal platform incorporating synthetic autonomously functioning immunoglobulin transgenes and a curated variable gene repertoire to generate diverse, high-affinity human antibodies for therapeutic discovery; access provided via non-exclusive licensing.
Transgenic mouse platform for human therapeutic antibody discovery
A validated transgenic animal platform incorporating synthetic autonomously functioning immunoglobulin transgenes and a curated variable gene repertoire to generate diverse, high-affinity human antibodies for therapeutic discovery; access provided via non-exclusive licensing.
Services
End-to-end discovery services that combine transgenic animal immunization, high-throughput screening (hybridoma and single-cell), NGS-based hit expansion, functional and kinetic characterization, and antibody engineering to deliver lead-quality antibody panels.
End-to-end discovery services that combine transgenic animal immunization, high-throughput screening (hybridoma and single-cell), NGS-based hit expansion, functional and kinetic characterization, and antibody engineering to deliver lead-quality antibody panels.
Expertise Areas
- Therapeutic antibody discovery
- Transgenic animal engineering for antibody generation
- Antibody engineering and reformatting for multispecifics and CAR constructs
- Immune repertoire design and analysis
Key Technologies
- Transgenic mouse-based in vivo antibody discovery
- Synthetic immunoglobulin transgene design and DNA synthesis
- Next-generation sequencing (NGS) for repertoire analysis and hit expansion
- Hybridoma generation and high-throughput screening
News & Updates
Announcement of new platforms and capabilities to enable partners to develop better antibody drugs faster.
Partnership to leverage AlivaMab Mouse technology for dermatology-focused antibody discovery.
Expansion of licensing rights for the AlivaMab Mouse platform following a pilot project.
Issuance of patents covering features of the AlivaMab Mouse and its antibodies.
Validation of the AlivaMab Mouse platform through a clinical-stage antibody candidate.
Featured in Nature Biopharma Dealmakers, highlighting Ablexis and AlivaMab Discovery Services' achievements.
Announcement of new platforms and capabilities to enable partners to develop better antibody drugs faster.
Partnership to leverage AlivaMab Mouse technology for dermatology-focused antibody discovery.
Expansion of licensing rights for the AlivaMab Mouse platform following a pilot project.
Issuance of patents covering features of the AlivaMab Mouse and its antibodies.
Validation of the AlivaMab Mouse platform through a clinical-stage antibody candidate.
Featured in Nature Biopharma Dealmakers, highlighting Ablexis and AlivaMab Discovery Services' achievements.